Background
As cardiac safety testing demands greater human relevance, a new model is changing the game. Non-human primate (cynomolgus, NHP-C) iPSC-derived ventricular cardiomyocytes are providing a powerful bridge between animal studies and human cardiac pharmacology.
Watch the webinar replay to hear from leading experts from Ncardia on how large-scale bioreactor production and advanced functional validation deliver >90% purity, consistent beating activity, and proven responses to key reference compounds.
See how these next-generation models are redefining predictive toxicology and advancing the future of cardiac safety. Register now.